Total Payments
$27,869
2024 Payments
$2,282
Companies
43
Transactions
796
Medicare Patients
1,188
Medicare Billing
$423,152
Payment Breakdown by Category
Consulting$12,200 (43.8%)
Food & Beverage$11,427 (41.0%)
Other$2,164 (7.8%)
Travel$1,726 (6.2%)
Education$352.89 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $12,200 | 3 | 43.8% |
| Food and Beverage | $11,427 | 779 | 41.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,164 | 3 | 7.8% |
| Travel and Lodging | $1,726 | 6 | 6.2% |
| Education | $352.89 | 5 | 1.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Pharmaceuticals, Inc | $10,071 | 48 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $9,152 | 94 | $0 (2024) |
| Alkermes, Inc. | $1,267 | 86 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $1,215 | 128 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $1,040 | 110 | $0 (2022) |
| ABBVIE INC. | $670.45 | 53 | $0 (2024) |
| Indivior Inc. | $626.45 | 31 | $0 (2024) |
| Lundbeck LLC | $567.20 | 45 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $386.20 | 26 | $0 (2024) |
| ITI, Inc. | $318.34 | 17 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,282 | 174 | Teva Pharmaceuticals USA, Inc. ($370.57) |
| 2023 | $1,802 | 123 | Teva Pharmaceuticals USA, Inc. ($303.30) |
| 2022 | $10,253 | 92 | Janssen Pharmaceuticals, Inc ($9,248) |
| 2021 | $1,462 | 91 | Alkermes, Inc. ($235.92) |
| 2020 | $996.30 | 58 | Teva Pharmaceuticals USA, Inc. ($244.45) |
| 2019 | $2,252 | 121 | Teva Pharmaceuticals USA, Inc. ($1,161) |
| 2018 | $2,237 | 69 | Teva Pharmaceuticals USA, Inc. ($1,202) |
| 2017 | $6,585 | 68 | Teva Pharmaceuticals USA, Inc. ($5,681) |
All Payment Transactions
796 individual payment records from CMS Open Payments — Page 1 of 32
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $27.67 | General |
| Category: PSYCHIATRY | ||||||
| 12/17/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $9.65 | General |
| Category: PSYCHIATRY | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $13.04 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/16/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $9.35 | General |
| Category: Neurology | ||||||
| 12/12/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $15.73 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $2.34 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/10/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $9.47 | General |
| Category: NEUROSCIENCE | ||||||
| 12/09/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $24.08 | General |
| Category: PSYCHIATRY | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $4.50 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $3.36 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $2.87 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $2.24 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $1.34 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $0.46 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/03/2024 | Noven Therapeutics, LLC | Xelstrym (Drug), Secuado | Food and Beverage | In-kind items and services | $14.10 | General |
| Category: ADHD | ||||||
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $13.11 | General |
| Category: Psychiatry/Psychology | ||||||
| 12/02/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $1.92 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/27/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $9.61 | General |
| Category: Neurology | ||||||
| 11/25/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $24.03 | General |
| Category: PSYCHIATRY | ||||||
| 11/21/2024 | Teva Pharmaceuticals USA, Inc. | UZEDY (Drug) | Food and Beverage | In-kind items and services | $12.78 | General |
| Category: Neurology | ||||||
| 11/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.09 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2024 | Sage Therapeutics, Inc. | ZURZUVAE (Drug) | Food and Beverage | In-kind items and services | $20.69 | General |
| Category: PSYCHIATRY/PSYCHOLOGY | ||||||
| 11/18/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $15.30 | General |
| Category: Neuropsychiatry | ||||||
| 11/15/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $3.29 | General |
| Category: Psychiatry/Psychology | ||||||
| 11/15/2024 | E.R. Squibb & Sons, L.L.C. | COBENFY (Drug) | Food and Beverage | Cash or cash equivalent | $0.44 | General |
| Category: Psychiatry/Psychology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 223 | 945 | $157,625 | $55,941 |
| 2022 | 11 | 317 | 1,445 | $453,230 | $126,272 |
| 2021 | 11 | 302 | 1,303 | $424,150 | $122,545 |
| 2020 | 12 | 346 | 1,352 | $440,365 | $118,393 |
Total Patients
1,188
Total Services
5,045
Medicare Billing
$423,152
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 61 | 253 | $46,805 | $22,853 | 48.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 32 | 221 | $55,250 | $19,711 | 35.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 31 | 93 | $20,925 | $5,572 | 26.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 33 | 37 | $11,470 | $3,152 | 27.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 25 | 26 | $9,100 | $2,964 | 32.6% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2023 | 20 | 248 | $12,400 | $863.22 | 7.0% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 21 | 67 | $1,675 | $827.45 | 49.4% |
| 90868 | Treatment using magnetic field to stimulate nerve cells in brain, subsequent delivery and management | Office | 2022 | 16 | 380 | $247,000 | $55,277 | 22.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 39 | 272 | $68,000 | $21,102 | 31.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 53 | 221 | $40,885 | $19,553 | 47.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 70 | $17,150 | $9,729 | 56.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 34 | 102 | $22,950 | $5,491 | 23.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 34 | 37 | $12,950 | $5,317 | 41.1% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 40 | 47 | $14,570 | $3,590 | 24.6% |
| 90867 | Treatment using magnetic field to stimulate nerve cells in brain, initial delivery and management | Office | 2022 | 14 | 15 | $13,500 | $2,149 | 15.9% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Office | 2022 | 15 | 15 | $4,500 | $2,134 | 47.4% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2022 | 43 | 103 | $2,575 | $1,272 | 49.4% |
| 96127 | Assessment of emotional or behavioral problems | Office | 2022 | 17 | 183 | $9,150 | $658.60 | 7.2% |
| 90868 | Transcranial magnetic stimulation treatment (stimulates nerve cells in brain to improve symptoms of depression), subsequent delivery and management, per session | Office | 2021 | 17 | 359 | $233,350 | $52,645 | 22.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 55 | 254 | $46,990 | $23,675 | 50.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 33 | 234 | $58,500 | $18,581 | 31.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 21 | 55 | $13,475 | $7,750 | 57.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 26 | 101 | $22,725 | $5,618 | 24.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 30 | 35 | $12,250 | $5,313 | 43.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 33 | 41 | $12,710 | $3,342 | 26.3% |
About Dr. Satish Narayan, MD
Dr. Satish Narayan, MD is a Addiction Medicine healthcare provider based in Plano, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1194787200.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Satish Narayan, MD has received a total of $27,869 in payments from pharmaceutical and medical device companies, with $2,282 received in 2024. These payments were reported across 796 transactions from 43 companies. The most common payment nature is "Consulting Fee" ($12,200).
As a Medicare-enrolled provider, Narayan has provided services to 1,188 Medicare beneficiaries, totaling 5,045 services with total Medicare billing of $423,152. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Addiction Medicine
- Other Specialties Addiction Psychiatry, Psychiatry
- Location Plano, TX
- Active Since 04/04/2006
- Last Updated 11/22/2022
- Taxonomy Code 2083A0300X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1194787200
Products in Payments
- SPRAVATO (Drug) $9,604
- AUSTEDO (Drug) $7,623
- REXULTI (Drug) $1,233
- LATUDA (Drug) $1,023
- SD809-TD (Drug) $763.36
- ARISTADA (Drug) $735.74
- VRAYLAR (Drug) $728.08
- SUBLOCADE (Drug) $558.06
- CAPLYTA (Drug) $479.02
- INVEGA SUSTENNA (Drug) $385.24
- TRINTELLIX (Drug) $362.18
- ABILIFY ASIMTUFII (Drug) $306.20
- Aristada 441 mg (Drug) $271.44
- UZEDY (Drug) $270.90
- ABILIFY MAINTENA (Drug) $260.82
- BELSOMRA (Drug) $252.88
- QELBREE (Drug) $239.85
- Brainsway Deep TMS (Device) $194.28
- Austedo XR (Drug) $162.41
- COBENFY (Drug) $143.30
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.